Phase III TRuE-AD3 study of Opzelura meets primary endpoint in atopic dermatitis – Incyte
Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase III TRuE-AD3 study evaluating the safety and efficacy of Opzelura (ruxolitinib cream) in children (age at least… read more.
